Axa S.A. Acquires 71,060 Shares of Danaher Corporation $DHR

Axa S.A. increased its holdings in shares of Danaher Corporation (NYSE:DHR) by 26.8% during the 2nd quarter, HoldingsChannel reports. The fund owned 335,777 shares of the conglomerate’s stock after buying an additional 71,060 shares during the period. Axa S.A.’s holdings in Danaher were worth $66,329,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Howard Hughes Medical Institute purchased a new position in shares of Danaher during the second quarter valued at approximately $27,000. Red Tortoise LLC increased its position in Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after buying an additional 98 shares in the last quarter. Ramirez Asset Management Inc. purchased a new position in Danaher during the second quarter valued at $40,000. Twin Peaks Wealth Advisors LLC bought a new stake in Danaher in the second quarter worth $51,000. Finally, Saudi Central Bank purchased a new stake in shares of Danaher in the first quarter worth $52,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Teri List sold 3,298 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the transaction, the director owned 20,762 shares in the company, valued at $4,702,593. This trade represents a 13.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 30,248 shares of company stock valued at $6,609,663. Insiders own 11.20% of the company’s stock.

Danaher Trading Down 0.4%

Shares of DHR stock opened at $223.51 on Wednesday. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23. The stock has a market capitalization of $157.87 billion, a P/E ratio of 46.08, a P/E/G ratio of 4.36 and a beta of 0.89. The firm’s 50 day moving average is $217.50 and its 200 day moving average is $205.01.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.71 EPS. Research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent analyst reports. Cowen reaffirmed a “buy” rating on shares of Danaher in a research report on Wednesday, October 22nd. Rothschild Redb cut shares of Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. The Goldman Sachs Group began coverage on shares of Danaher in a research note on Tuesday. They issued a “buy” rating and a $265.00 target price on the stock. Deutsche Bank Aktiengesellschaft raised their price target on shares of Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a research report on Wednesday, October 22nd. Finally, Redburn Partners set a $220.00 price objective on shares of Danaher in a report on Wednesday, October 8th. Twenty-one research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $246.79.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.